Identification of tumor antigen derived peptides having the potential to promise candidates for cancer vaccine therapy from prostate cancer patients

• Project/Area Number: 20791130
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Urology
• Research Institution: Kinki University
• Principal Investigator: MINAMI Takafumi Kinki University, 医学部, 助教 (70340809)
• Project Period (FY): 2008 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2008: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
• Keywords: 前立腺癌 / 癌ワクチン / HLA-A3 / supertype / alleles / HLA-A3 supertype alleles / ペプチドワクチン / 潜伏感染

Research Abstract

Peripheral blood mononuclear cells(PBMCs) were obtained from prostate cancer patients who had provided a written informed consent. Fifty milliliter of peripheral blood was obtained, and the PBMCs were prepared by Ficoll-Conray density gradient centrifugation. The expression of HLA-A11,-A31,and -A33 molecules on the PBMCs was determined by flow cytometry using these antibodies-anti-HLA-A11, anti-HLA-A31, anti-HLA-A33-and FITC-conjugated anti-mouse immunoglobulin G(IgG) monoclonal antibodies.
7 prostate cancer-related antigens(SART2, CypB, PTH-rP, HER2neu, EGFR, MRP3, EZH2) prepared based on the binding motifs to the MHC-class I alleles.
To generate LNCaP sublines expressing each of the HLA-A11, -A31, and-A33 molecules, an HLA-A1101, -A3101, or. A3303 plasmid cDNA was inserted into the eukaryotic expression vector pCR3.1.
20 patient's peripheral blood mononuclear cells(PBMCs) were obtained from prostate cancer patients. The expression of HLA-A11, -A31, -A33 molecules on the PBMCs was determined by flow cytometry using these antibodies.